Abstract:Purpose: The purpose of this preliminary study was to assess the feasibility and efficacy of intraoperative, ultrasound-guided 125I seed interstitial brachytherapy for unresectable pancreatic carcinoma.Materials and Methods: 27 patients were diagnosed with unresectable pancreatic carcinoma that was not considered curable during laparotomy. Twelve patients with were diagnosed with stage II/III carcinoma, and fifteen patients with stage IV carcinoma. These patients were treated with 125I seed implantation guided by intraoperative ultrasound. The matched peripheral doses (MPD) of 125I resulting from seed implantation ranged from 110 Gy to 160 Gy. A subset of seven patients received additional external beam radiotherapy (EBRT) with a total dose of EBRT administered between 3500∼4500 cGy at 200 cGy per fraction. Six patients received 2–6 cycles of chemotherapy.Results: Of the 20 patients treated with 125I seed implantation only, 85% (17/20) experienced pain relief, while 15% (3/20) did not respond. The median time of pain relief was 5 days and ranged from 1 to 30 days. The overall median survival time in this study was 8 months (95% CI: 6.6–9.4). One- and two-year survival rates of 19.5% and 7.8% were observed, and local control of disease was achieved in 74% patients (20/27). For stage II and III patients, the one- and two-year survival rates were 33.9% and 16.9%, respectively, and the median survival was 10 months (95% CI: 7.8–12.2). In contrast, for stage IV patients the one-and two-year survival rates were 7.1% and 0%, with a median survival of 6 months (95% CI: 2.3–9.7). For patients receiving seed implant plus EBRT versus seed only, the median survival times were 9 and 7 months, respectively (p = 0.1008). For patients receiving seed implants and chemotherapy versus seeds only, the median survival rates were the same, 8 months (p = 0.2954). There were no deaths related to 125I seed implantation.Ultrasound scan show the seed distribution in tumor after seed implant. Purpose: The purpose of this preliminary study was to assess the feasibility and efficacy of intraoperative, ultrasound-guided 125I seed interstitial brachytherapy for unresectable pancreatic carcinoma. Materials and Methods: 27 patients were diagnosed with unresectable pancreatic carcinoma that was not considered curable during laparotomy. Twelve patients with were diagnosed with stage II/III carcinoma, and fifteen patients with stage IV carcinoma. These patients were treated with 125I seed implantation guided by intraoperative ultrasound. The matched peripheral doses (MPD) of 125I resulting from seed implantation ranged from 110 Gy to 160 Gy. A subset of seven patients received additional external beam radiotherapy (EBRT) with a total dose of EBRT administered between 3500∼4500 cGy at 200 cGy per fraction. Six patients received 2–6 cycles of chemotherapy. Results: Of the 20 patients treated with 125I seed implantation only, 85% (17/20) experienced pain relief, while 15% (3/20) did not respond. The median time of pain relief was 5 days and ranged from 1 to 30 days. The overall median survival time in this study was 8 months (95% CI: 6.6–9.4). One- and two-year survival rates of 19.5% and 7.8% were observed, and local control of disease was achieved in 74% patients (20/27). For stage II and III patients, the one- and two-year survival rates were 33.9% and 16.9%, respectively, and the median survival was 10 months (95% CI: 7.8–12.2). In contrast, for stage IV patients the one-and two-year survival rates were 7.1% and 0%, with a median survival of 6 months (95% CI: 2.3–9.7). For patients receiving seed implant plus EBRT versus seed only, the median survival times were 9 and 7 months, respectively (p = 0.1008). For patients receiving seed implants and chemotherapy versus seeds only, the median survival rates were the same, 8 months (p = 0.2954). There were no deaths related to 125I seed implantation. Ultrasound scan show the seed distribution in tumor after seed implant.

A Pilot Study of Intraluminal Brachytherapy Using 125I Seed Strand for Locally Advanced Pancreatic Ductal Adenocarcinoma with Obstructive Jaundice.

Comparison of Intraluminal Brachytherapy Combined with and Without Stent Placement for Treatment of Obstructive Jaundice Induced by Tumor Thrombus.

The Use of 125I Seed Strands for Intraluminal Brachytherapy of Malignant Obstructive Jaundice

Malignant Obstructive Jaundice Treated with Intraluminal Placement of Iodine-125 Seed Strands and Metal Stents: an Analysis of Long-Term Outcomes and Prognostic Features

Preliminary application of brachytherapy with double-strand 125I seeds and biliary drainage for malignant obstructive jaundice

HDR-^192Ir Intraluminal Brachytherapy in Treatment of Malignant Obstructive Jaundice

Malignant Obstructive Jaundice Treated by Intraluminal Brachytherapy Combined with Stent Placement or Stent Implantation Alone

Brachytherapy by Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

Ultrasound-guided interstitial ~(125)I seed implantation in the treatment of locally advanced pancreatic carcinoma

Intrabiliary Radiofrequency-Enhanced Local Chemotherapeutic Deposit in Bile Duct Walls Using a Needle-Integrated Balloon Catheter: A Feasibility Study on Survival Pigs

An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma

Malignant obstructive jaundice - brachytherapy as a tool for palliation

Intraoperative Ultrasound-Guided 125I Implantation in the Treatment of Unresectable Pancreatic Carcinoma

Iodine-125 Seeds Combined with Biliary Stent Placement Versus Stent Placement Alone for Unresectable Malignant Biliary Obstruction: A Meta-Analysis of Randomized Controlled Trials

Clinical Studies of Pancreatic Cancer Treated by Endovascular Implantation of Iodine-125 Seeds Strand

Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice

Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma

[Intraoperative 125I Brachytherapy Combined with Chemotherapy for Pancreatic Cancer].

Postoperative Iodine-125 Interstitial Brachytherapy for the Early Stages of Minor Salivary Gland Carcinomas of the Lip and Buccal Mucosa with Positive or Close Margins

Clinical outcomes of intraluminal Iodine-125 seed strand brachytherapy and percutaneous nephrostomy in patients with ureteral carcinoma

Safety and Efficacy of IBI343 (Anti-Claudin18.2 Antibody-Drug Conjugate) in Patients with Advanced Pancreatic Ductal Adenocarcinoma or Biliary Tract Cancer: Preliminary Results from a Phase 1 Study.